Macro­Gen­ics, Ab­b­Vie stop de­vel­op­ment of part­nered ADC

Macro­Gen­ics and Ab­b­Vie plan to end de­vel­op­ment of their ADAM9-tar­get­ed an­ti­body-drug con­ju­gate af­ter ear­ly tri­al da­ta dis­ap­point­ed.

The Mary­land-based Macro­Gen­ics

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER